JUN 28, 2016 10:00 AM PDT

The power of multiplexing with Luminex technology

  • Senior R&D Manager and Immunoassay Strategy Lead, Biosciences Division, Thermo Fisher Scientific
      David's Ph.D. and postdoctoral work focused on the study of G protein-coupled receptor signaling and thrombosis. Following his academic training, he led multiplexed immunoassay automation efforts at a Luminex® partnering company. In 2009, David joined Thermo Fisher Scientific working on the development of novel immunoassay platforms such as the ProtoPlex™ Immune Response Assay. Now as Sr. Manager and immunoassay strategy lead, David pursues next-gen immunoassay platform development which includes working with translational investigators to identify serum-based biomarkers in cancer, autoimmunity, and inflammation.


    Translational investigators require powerful immunoassays for the targeted detection of proteomic biomarkers with the goal of studying human health. Cytokine profiling tools are critical to understanding how acute and chronic inflammatory conditions cancer and autoimmunity. Invitrogen™ immunoassay tools from Thermo Fisher provide sensitive and specific detection of target proteins across a range of applications and platforms, including western blotting, ELISA, and Luminex™ xMAP™ multiplexed bead-based assays.  For the latter, Luminex assays produce rich data sets (30+ analyte concentrations) from a small sample volume with sensitivity and specificity.   This presentation will highlight key characteristics of the Invitrogen Luminex multiplexed immunoassay platform and how it can accelerate quantification of relevant protein markers.  

    Show Resources
    Show Resources
    • See more
    Connect with us